Vitrolife AB (publ) - Interim report Q3, 2023: Profitable growth globally despite headwind in the U.S.
- Q3 sales increased by 6%, reaching SEK 848 million. Gross margin improved to 55.7%. Operating cash flow increased to SEK 214 million. Net income rose to SEK 122 million.
- Americas sales decreased by 8% in Q3.
Third quarter
- Sales of
SEK 848 (798) million, an increase of6% , or7% excluding discontinued business. In local currencies the growth was2% and excluding discontinued business3% . - Sales, in local currencies and excluding discontinued business, increased by
5% in APAC and14% in EMEA, whileAmericas decreased by8% . - Sales, in local currencies and excluding discontinued business, increased by
8% in Consumables and14% in Technologies, while Genetic Services decreased by5% . - Gross margin increased to
55.7% (53.6). - Operating income before depreciation and amortisation (EBITDA) was
SEK 287 (276) million, giving an EBITDA margin of33.9% (34.5). The EBITDA is stronger given the non-recurring income for the quarter last year. - Operating cash flow increased to
SEK 214 million (200). - Net income increased to
SEK 122 (108) million, resulting in earnings per share ofSEK 0.90 (0.80).
First nine months
- Sales of
SEK 2,607 (2,379) million, an increase of10% , or11% excluding discontinued business. In local currencies, growth was4% and excluding discontinued business5% . - Sales, in local currencies and excluding discontinued business, increased by
15% in APAC and6% in EMEA, whileAmericas decreased by3% . - Sales, in local currencies and excluding discontinued business, increased by
12% in Consumables and4% in Technologies, while Genetic Services decreased by1% . - Gross margin increased to
56.1% (55.3). - Operating income before depreciation and amortisation (EBITDA) was
SEK 842 (777) million. Adjusted for non-recurring costs, EBITDA wasSEK 868 (777) million, giving an EBITDA margin of33.3% (32.6). - Operating cash flow increased to
SEK 586 million (470). - Net income increased
SEK 328 (321) million, resulting in earnings per share ofSEK 2.42 (2.36).
VITROLIFE AB (publ)
Bronwyn Brophy O´Connor, CEO
This disclosure contains information that Vitrolife AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014) and the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 27-10-2023 08:00 CET.
Contact:
Patrik Tolf, CFO, phone +46 (0) 31 766 90 21
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
The following files are available for download:
Interim report Q3, 2023 |
View original content:https://www.prnewswire.com/news-releases/vitrolife-ab-publ---interim-report-q3-2023-profitable-growth-globally-despite-headwind-in-the-us-301969884.html
SOURCE Vitrolife AB (publ)
FAQ
What was the sales growth in Q3?
What was the gross margin in Q3?
How much did the operating cash flow increase in Q3?
What was the net income in Q3?